title: Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
abstract: There is some evidence from in vitro studies as well as case series that patients with documented platinum resistance will respond to platinum after a nonplatinum drug. In addition, retrospective case studies have demonstrated the difficulty in determining if delaying second platinum is detrimental or beneficial. For that reason, a prospective Italian randomized trial conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) Group (MITO-8), comparing nonplatinum with platinum-based therapy is being performed to assess the effects of delaying platinum on survival.
authors.affiliation: UCL Cancer Institute, UCLH & UCL Biomedical Research Centre, University College London, London, United Kingdom. j.ledermann@ctc.ucl.ac.uk
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Ledermann
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017671:Platinum Compounds / Q000008:administration & dosage*; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents; D017671:Platinum Compounds